Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?


Rexahn Pharmaceuticals (RNN) Continues to Spike on Potential Cancer Pill, Roth Upgrade

By  +Follow January 13, 2014 10:17AM
Tickers Mentioned:

Shares in Rexahn Pharmaceuticals (RNN) jumped nearly 40 percent on Monday, continuing a bull-run that has the stock up over 150 percent since Thursday and over 265 percent in the last month on a promising potential cancer treatment and the initiation of relatively bullish coverage from Roth Capital Markets analysts.

RNN’s RX-3117 Could be Alternative for Eli Lilly’s Gemzar

Driving the current growth-spurt is the announcement of the initation of Phase 1b to study the safety and efficacy of RX-3117, Rexahn’s lead drug candidate, in cancer patients with solid tumors. The hype surrounding RX-3117 is considerable given that it has to potential to function as an oral to Eli Lilly’s (LLY) Gemzar.

"The initiation of this Phase I clinical trial of RX-3117 represents an important milestone for Rexahn," said CEO Peter D. Suzdak, Ph.D. "This compound is exciting to work with, as it has a unique profile with demonstrated activity against gemcitabine-resistant human cancer cells. We were pleased to see reduced side effect liability and oral bioavailability in cancer patients in our initial exploratory Phase I clinical trial conducted in Europe, and we believe that RX-3117 may represent a significant advancement in the treatment of cancer patients with solid tumors."

Gemzar is an injectable drug that results in resistance for 1 out of 4 patients, making an alternative that functions in pill form one with considerable commercial potential.

Analyst Seems Convinced

Also helping boost shares over the past few days was the news from Thursday that Roth Capital Markets’ Joe Pantiginis had initiated coverage on the stock at a “buy” rating with a price target of $3, still nearly double the current share price even after the spike in price.

Along with the considerable potential for RX-3117, the company boasts nearly $15 million in cash as well as over $5 million in new funding, giving it enough money to carry it for two years.


DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.

Liked What You Read? Join Equities.com and Connect With Your Favorite Financial Experts FOR FREE! Members of Equities.com gain access to our leading financial news and content, active social investment community, proprietary research tools including the 2014 Small-Cap Stars, E.V.A. reports and more.

Results for rnn
5 Mar 15 19:19:06
RNN -1.28% Stock Charts $RNN Rexahn Pharmaceuticals Inc. (NYSE MKT) Last Updated: 03/05/2015 21:19:06 RNN Stoc http://t.co/F1rY51eVOk
Edwin Claudio
5 Mar 15 18:18:28
$RNN I got a good feeling
Mark Trader
5 Mar 15 13:39:30
The last http://t.co/8hGh2pxMWQ alert popped over 400%. So sweet and free to sign up. $OGZP $VGGL $GST $RNN $YGE $EXK $REN
Wall Street
5 Mar 15 09:58:57
Article about a new type of penny stock website. http://t.co/KjdM27IdTR $GDP $GERN $ACI $SFY $VLCCF $RNN $BTG $PGH $HERO
5 Mar 15 06:26:24
$RNN bio that hasn't run with a golden cross approaching.
5 Mar 15 05:19:13
$RNN $AEZS $ABIO on watch for today
Wall Street
5 Mar 15 02:09:33
http://t.co/J58EN2Hzp9 has the most reliable picks in the market. The move fast and never fail. $EOX $RNN $GALE $MONIF $SVM $LBSR
4 Mar 15 21:05:40
$RNN_$0.780_Director of Business Development, will present at the BIO-Europe Spring® 2015 Conference in France on March 10, 2015 at 2:15 PM
High Octane
4 Mar 15 20:17:15
$RNN http://t.co/8kKvYYRqtk
By  +Follow January 13, 2014 10:17AM



blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.